RAC 0.93% $1.62 race oncology ltd

[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-40

  1. 6,824 Posts.
    lightbulb Created with Sketch. 1748
    I know…just wondering what could be under wraps.

    The interviewer started with “flagship drug” - well that is standard terminology and then Dr.T responded with “lead asset” which is another industry term but given R&D work who knows what’s cooking?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.